02065nas a2200241 4500008004100000022001400041245008000055210006900135260000800204300000800212490000700220520134200227653001801569653002401587653001101611653001401622653000901636100001801645700001701663700001701680700001901697856010701716 2019 eng d a1530-993200aMapping fusogenicity of ciprofloxacin-loaded liposomes with bacterial cells0 aMapping fusogenicity of ciprofloxacinloaded liposomes with bacte cJUL a1800 v203 a

The process of liposome fusion with cellular membrane plays key role in delivering encapsulated drug molecule into the cell. This process becomes very important for molecules having low permeability as they fail to reach the site of action located inside the cell. Ciprofloxacin (CIP), a broad-spectrum BCS class IV antibiotic, has poor permeability. In the present work, CIP-loaded liposomes were prepared using solvent evaporation method and optimized by 3(2) factorial design approach. The optimized batch of CIP-loaded liposomes was characterized for size, entrapment efficiency, zeta potential, FTIR, and microbial susceptibility study on Staphylococcus aureus (gram-positive bacteria) and Escherichia coli (gram-negative bacteria). Confocal microscopy was used to study the fusogenicity process of CIP-loaded liposomes with bacterial cells. Additionally, the kinetics of fusogenicity process was studied using SAXS for the first time. Surprisingly, the rate of fusion of CIP-loaded liposomes with cell wall of S. aureus was twice when compared to the cell wall of E. coli. It is believed that the current work can act as a roadmap in selection of proper excipients while developing formulations which would expedite the fusogenicity and may execute pharmacological activity of poorly penetrable drug molecules at lower dose.

10aciprofloxacin10aconfocal microscopy10afusion10aliposomes10aSAXS1 aPatil, Runali1 aTorris, Arun1 aBhat, Suresh1 aPatil, Sharvil uhttps://library.ncl.res.in/content/mapping-fusogenicity-ciprofloxacin-loaded-liposomes-bacterial-cells01933nas a2200193 4500008004100000020001400041245008400055210006900139260000800208300001600216490000700232520135200239100002501591700001701616700001701633700002301650700001901673856004701692 2021 eng d a2191-164900aResveratrol loaded cubic phase nanoparticles with enhanced oral bioavailability0 aResveratrol loaded cubic phase nanoparticles with enhanced oral  cDEC a1108 - 11180 v113 aResveratrol (RES), a naturally occurring hydrophobic polyphenolic compound, has shown potential anticancer activity. However, due to low aqueous solubility and extensive first pass metabolism (primarily by cytochrome enzymes), it shows poor oral bioavailability. In the present work, novel RES loaded cubosomes of glycerol monooleate (GMO) and Gelucire 44/14 (GL44) (RES-Cubs) were prepared. RES-Cubs were prepared by emulsion evaporation technique and optimized using 32 factorial design. The optimized RES-Cubs were assessed for particle size, zeta potential, entrapment efficiency, FTIR, TEM, SAXS, in vitro resveratrol release and oral bioavailability. RES-Cubs showed an average particle size of 121.7 ± 2.54 nm with adequate entrapment efficiency of about 82.0 ± 2.35% w/w. The analysis of SAXS profile of RES-Cubs revealed Pn3m crystallographic space group containing diamond cubic phase. In vitro RES release profile of RES-Cubs exhibited markedly sustained release of resveratrol. Furthermore, RES-Cubs demonstrated considerable enhancement in oral bioavailability (ninefold) of resveratrol as compared to RES alone. The developed RES loaded cubosomes bearing cytochrome enzyme inhibitor property can act as promising nanocarrier in the delivery of lipophilic drugs with a drawback of in vivo degradation by cytochrome enzymes.1 aRawat, Neeraj, Kumar1 aTorris, Arun1 aBhat, Suresh1 aMahadik, Kakasaheb1 aPatil, Sharvil uhttps://doi.org/10.1007/s12668-021-00892-902779nas a2200217 4500008004100000245010100041210006900142260000900211300001400220490000700234520201600241100002502257700002402282700002102306700002702327700001902354700001702373700001802390700002402408856012902432 2023 eng d00aRivaroxaban eutectics with improved solubility, dissolution rates, bioavailability and stability0 aRivaroxaban eutectics with improved solubility dissolution rates cJUN  a3253-32630 v253 a

Rivaroxaban (RXB) is a direct factor Xa inhibitor used for the treatment of deep vein thrombosis (DVT, a blood clot in the leg) and pulmonary embolism (PE, a blood clot in the lung) and to prevent blood clots in atrial fibrillation following hip or knee surgery. However, RXB suffers from poor solubility that hinders its broader application. Although its cocrystals are reported for solubility enhancement, the methodology used to prepare multi-component crystals is complex. Also, it uses hazardous solvents to develop cocrystals. We have prepared eutectics of RXB with caffeic acid (CAA), coumaric acid (CA), fumaric acid (FA), succinic acid (SA), mandelic acid (MA) and trimesic acid (TA) and analyzed them using hot stage microscopy (HSM), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), and fourier transform infrared spectroscopy (FTIR) techniques. The saturation solubility and dissolution rate profiles were also obtained to investigate the effect of eutectics on these parameters. Amongst all the coformers tested, coformers CAA, CA, and FA showed significant enhancement in the solubility of RXB. The powder dissolution rate of the eutectics showed considerable enhancement compared to that of RXB. In vivo pharmacokinetic study was carried out for RXB-CAA, RXB-CA and RXB-FA in rats and compared with RXB, which showed 1.5 and 1.4 times enhancement in relative bioavailability for RXB-CAA and RXB-CA, respectively. Stability studies were carried out as per ICH guidelines for all the eutectics, which revealed excellent stability over six months under accelerated (40 degrees C and 75%) conditions and twelve months under long-term (30 degrees C and 60% RH) conditions. The DFT studies carried out using the B3LYP/TZVP level of theory revealed higher Gibbs free interaction energy (Delta G(int)) for homosynthons (drugMIDLINE HORIZONTAL ELLIPSISdrug and coformerMIDLINE HORIZONTAL ELLIPSIScoformer) than heterosynthons (drugMIDLINE HORIZONTAL ELLIPSIScoformer).

1 aShaligram, Parth, S.1 aGeorge, Christy, P.1 aSharma, Himanshu1 aMahadik, Kakasaheb, R.1 aPatil, Sharvil1 aVanka, Kumar1 aArulmozhi, S.1 aGonnade, Rajesh, G. uhttps://library.ncl.res.in/content/rivaroxaban-eutectics-improved-solubility-dissolution-rates-bioavailability-and-stability02742nas a2200241 4500008004100000022001400041245010300055210006900158260000800227300001200235490000700247520195100254653001202205653002002217653001402237653001802251653002102269100002302290700002102313700002402334700001902358856012302377 2026 eng d a0724-874100aNovel cocrystal of quercetagetin: in vitro and in vivo insights into biopharmaceutical performance0 aNovel cocrystal of quercetagetin in vitro and in vivo insights i cMAR a927-9390 v433 a

Purpose Quercetagetin (QTGN) is a naturally occurring flavonol predominantly sourced from marigold flowers and possesses notable therapeutic potential, including antidiabetic, anticancer, antioxidant, anti-inflammatory, and antiviral properties. However, poor aqueous solubility and in turn bioavailability restrict therapeutic utility of QTGN. Crystal engineering is one of the approaches proven to be fruitful in resolving the solubility issues of many active pharmaceutical ingredients (APIs). Method In the present work, a cocrystal of QTGN using betaine (BET) as coformer viz. Quercetagetin & sdot;betaine & sdot;ethanol (QTGN & sdot;BET & sdot;EtOH) was synthesized using the solvent evaporation method. It was further characterized using Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Thermogravimetric analysis (TGA), Powder X-ray diffraction (PXRD), and single crystal XRD (SCXRD). Result FTIR studies confirmed hydrogen bonding between QTGN and BET. PXRD studies showed formation of new crystalline phase. The prepared cocrystal had stoichiometric ratio of 1:1:1 between QTGN, BET, and ethanol forming cocrystal ethanolate and shared robust hydroxyl & ctdot;carboxylate supramolecular synthon as confirmed by TGA and SCXRD, respectively. Equilibrium solubility study and in vitro dissolution study showed a significant improvement (p < 0.0001) in aqueous solubility of QTGN upon its cocrystallization with BET. Furthermore, in vivo pharmacokinetic study revealed a 1.28-fold increase in bioavailability of QTGN when formulated as cocrystal solvate. The prepared cocrystal was found to be stable over a period of six months at 40 degrees C and 75% RH when analyzed using PXRD studies. Conclusion The current work represents a frontier in pharmaceutical formulation, providing a means to fully harness the therapeutic potential of QTGN using cocrystal approach.

10abetaine10aBioavailability10acocrystal10aquercetagetin10aUSP apparatus IV1 aSuryawanshi, Smita1 aShaligram, Parth1 aGonnade, Rajesh, G.1 aPatil, Sharvil uhttps://library.ncl.res.in/content/novel-cocrystal-quercetagetin-vitro-and-vivo-insights-biopharmaceutical-performance